Promoting Health through Vitamin D Therapeutics

Improving People's Lives by Treating and Preventing the Clinical Consequences of
Vitamin D Insufficiency and Secondary Hyperparathyroidism

  

Recent News:

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients
September 04, 2018

OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
July 16, 2018

OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE in Japan
October 12, 2017
 
     
 

 

  

© 2018 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use